Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections

被引:123
|
作者
Thangamani, Shankar [1 ]
Younis, Waleed [1 ]
Seleem, Mohamed N. [1 ]
机构
[1] Purdue Univ, Coll Vet Med, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
CA-MRSA SKIN; IN-VITRO; AUREUS; ANTIBIOTICS; INFLAMMATION; ANTIOXIDANT; EXPRESSION; SUSCEPTIBILITY; CHOLESTEROL; INHIBITION;
D O I
10.1038/srep11596
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Novel antimicrobials and new approaches to developing them are urgently needed. Repurposing already-approved drugs with well-characterized toxicology and pharmacology is a novel way to reduce the time, cost, and risk associated with antibiotic innovation. Ebselen, an organoselenium compound, is known to be clinically safe and has a well-known pharmacology profile. It has shown potent bactericidal activity against multidrug-resistant clinical isolates of staphylococcus aureus, including methicillin- and vancomycin-resistant S. aureus (MRSA and VRSA). We demonstrated that ebselen acts through inhibition of protein synthesis and subsequently inhibited toxin production in MRSA. Additionally, ebselen was remarkably active and significantly reduced established staphylococcal biofilms. The therapeutic efficacy of ebselen was evaluated in a mouse model of staphylococcal skin infections. Ebselen 1% and 2% significantly reduced the bacterial load and the levels of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), and monocyte chemo attractant protein-1 (MCP-1) in MRSA USA300 skin lesions. Furthermore, it acts synergistically with traditional antimicrobials. This study provides evidence that ebselen has great potential for topical treatment of MRSA skin infections and lays the foundation for further analysis and development of ebselen as a potential treatment for multidrug-resistant staphylococcal infections.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections
    Shankar Thangamani
    Waleed Younis
    Mohamed N. Seleem
    Scientific Reports, 5
  • [2] Repurposing the Ionophore, PBT2, for Treatment of Multidrug-Resistant Neisseria gonorrhoeae Infections
    Jen, Freda E-C
    Edwards, Jennifer L.
    El-Deeb, Ibrahim M.
    Walker, Mark J.
    von Itzstein, Mark
    Jennings, Michael P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [3] Colistin for the treatment of multidrug-resistant infections
    LaPlante, Kerry
    Cusumano, Jaclyn
    Tillotson, Glenn
    LANCET INFECTIOUS DISEASES, 2018, 18 (11): : 1174 - 1175
  • [4] Niclosamide as a Repurposing Drug against Corynebacterium striatum Multidrug-Resistant Infections
    Folliero, Veronica
    Dell'Annunziata, Federica
    Roscetto, Emanuela
    Cammarota, Marcella
    De Filippis, Anna
    Schiraldi, Chiara
    Catania, Maria Rosaria
    Casolaro, Vincenzo
    Perrella, Alessandro
    Galdiero, Massimiliano
    Franci, Gianluigi
    ANTIBIOTICS-BASEL, 2022, 11 (05):
  • [5] Monobactam Treatment of multidrug-resistant Enterobacteriaceae infections
    Ahmad, Mohammad Naiyaz
    Dasgupta, Arunava
    Chopra, Sidharth
    DRUGS OF THE FUTURE, 2023, 48 (02) : 81 - 91
  • [6] Repurposing Thiram and Disulfiram as Antibacterial Agents for Multidrug-Resistant Staphylococcus aureus Infections
    Long, Timothy E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
  • [7] New antibiotics for the treatment of infections by multidrug-resistant microorganisms
    Escola-Verge, Laura
    Los-Arcos, Ibai
    Almirante, Benito
    MEDICINA CLINICA, 2020, 154 (09): : 351 - 357
  • [8] Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
    Lee, Nan-Yao
    Ko, Wen-Chien
    Hsueh, Po-Ren
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [9] To fight multidrug-resistant infections
    不详
    LAB ANIMAL, 2018, 47 (08) : 213 - 213
  • [10] A Promising Target for Treatment of Multidrug-Resistant Bacterial Infections
    Davey, Martin S.
    Tyrrell, Jonathan M.
    Howe, Robin A.
    Walsh, Timothy R.
    Moser, Bernhard
    Toleman, Mark A.
    Eberl, Matthias
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3635 - 3636